Visioneering Technologies, Inc. maker of NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, unveiled significant findings at the Global Specialty Lens Symposium (GSLS). The data is from a clinical trial led by professor Gonzalo Carracedo (Universidad Complutense de Madrid) on astigmatism correction in myopic children and updates from VTI’s ongoing PROTECT study.
ASTIGMATISM STUDY KEY FINDINGS
Presented in a poster session and a presentation titled, “Evaluation of Visual Acuity with Multifocal Catenary Curve-Based Contact Lens Design in Different Degrees of Astigmatism”:
- Astigmatic Vision Correction:
- 100% success with astigmatism ≤ 2.00 D.
- 83% success with astigmatism ≤ 3.00 D.
- Patient Experience:
- 77% rated overall visual quality as satisfactory or better.
- 83% rated overall comfort as satisfactory or better.
- Additional Benefits: Preserved stereopsis and compatibility across pupil sizes.
This clinical trial validated the NaturalVue Multifocal lens astigmatism correction indication of up to 2.00 D. NaturalVue Multifocal, can correct (vs. mask) an extensive range of astigmatism by enabling both meridians to focus simultaneously due to its patented extended depth of focus design.
Ashley Tuan, OD, VTI’s Chief Medical Officer, says, “Professor Carracedo’s study highlights NaturalVue’s ability to provide exceptional vision while managing myopia, empowering kids to thrive without compromise.”
This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing randomized clinical trial (RCT) studying its effectiveness for myopia progression control.